Essential thrombocythemia (ET) is one of those “looks benign until it isn’t” Step diagnoses: sky-high platelets, paradoxical clotting and bleeding, and a classic myeloproliferative vibe. The key is to recognize the pattern quickly, sketch it once, and then recall the high-yield associations on test day.
The one-liner (shareable)
Essential thrombocythemia = a myeloproliferative neoplasm with clonal megakaryocyte proliferation → sustained thrombocytosis → thrombosis + mucocutaneous bleeding (acquired vWF dysfunction).
Draw-it-out method (visual mnemonic)
Sketch this in 20 seconds
Draw a factory labeled “Marrow” producing platelets.
- Big “MEGA” worker (a megakaryocyte) running the factory
- Conveyor belt spitting out tons of platelets:
||||||||||||| - Split the output into two arrows:
- Arrow A: CLOT (a thrombus)
- Arrow B: BLEED (a nosebleed)
Add a sticky note on the “BLEED” arrow: “acquired vWF ↓” (from excessive platelet binding/clearance of vWF multimers).
Mnemonic phrase: “Too many plates → traffic jams (clots) + broken dishes (bleeding).”
What ET is (and what bucket it’s in)
- Category: Myeloproliferative neoplasm (MPN)
- Core feature: Sustained thrombocytosis due to clonal megakaryocyte proliferation
- Common driver mutations:
- JAK2 (most common)
- CALR
- MPL
Step framing: If you see isolated thrombocytosis with MPN genetics + megakaryocyte proliferation, ET should be high on the list.
High-yield clinical clues
Symptoms & signs
- Thrombosis
- DVT/PE, stroke/TIA, MI
- Budd–Chiari can be seen across MPNs (think “hypercoagulable marrow disorders”)
- Bleeding (counterintuitive!)
- Epistaxis, gum bleeding, easy bruising
- Classically due to acquired von Willebrand syndrome when platelets are very high
- Microvascular issues
- Headache, dizziness, visual changes
- Erythromelalgia (burning pain/redness in hands/feet; can improve with antiplatelet therapy)
Physical/labs
- Platelets often > 450,000/µL, sometimes > 1,000,000/µL
- May have splenomegaly (less dramatic than myelofibrosis, but can happen)
The “paradox” you must remember: clotting + bleeding
ET patients can clot because of increased platelet number and activation, yet bleed because:
- Very high platelets can lead to loss of high–molecular-weight vWF multimers → decreased platelet adhesion → mucocutaneous bleeding
- Board-style clue: platelets extremely high + bleeding symptoms → think acquired vWF dysfunction
Peripheral smear & bone marrow: what to picture
Peripheral smear
- Marked thrombocytosis
- Large/giant platelets may be seen
Bone marrow (high-yield pattern)
- Increased megakaryocytes, often large, mature, hyperlobulated (“staghorn”) nuclei
- Compare in your head:
- ET: megakaryocyte proliferation predominates
- Polycythemia vera: RBC mass predominates
- Primary myelofibrosis: atypical megakaryocytes + fibrosis (later “dry tap”)
Diagnosis: quick framework (Step-style)
ET is diagnosed after excluding reactive causes and other MPNs.
Key moves
- Rule out reactive thrombocytosis (infection, inflammation, iron deficiency, malignancy, postsplenectomy)
- Look for MPN mutations (JAK2/CALR/MPL)
- Bone marrow supportive findings (megakaryocytic proliferation)
Treatment: what Step wants you to know
Management depends on thrombosis risk and symptoms.
Common approaches (high-yield)
- Low-dose aspirin for microvascular symptoms and thrombosis prevention (when appropriate)
- Cytoreduction for higher-risk patients:
- Hydroxyurea (classic Step answer for cytoreduction in MPNs)
- If bleeding with extreme thrombocytosis: think acquired vWF → management may involve platelet reduction (don’t reflexively “more antiplatelet” if they’re actively bleeding)
Test-taking tip: When you see ET + bleeding, the question is often really about acquired vWF syndrome, not “platelets are low.”
ET vs reactive thrombocytosis (fast comparison)
| Feature | Essential thrombocythemia (ET) | Reactive thrombocytosis |
|---|---|---|
| Cause | Clonal MPN | Secondary to inflammation, infection, iron deficiency, etc. |
| Mutations | JAK2/CALR/MPL | Absent |
| Bone marrow | ↑ megakaryocytes (large, hyperlobulated) | Reactive changes |
| Complications | Thrombosis + bleeding | Usually fewer thrombotic/bleeding issues (depends on cause) |
| Spleen | Can be enlarged | Typically normal (unless underlying condition) |
Exam traps & high-yield pearls
- Bleeding with very high platelets is real: suspect acquired vWF dysfunction.
- MPNs love thrombosis: if you see unusual clot locations (e.g., hepatic vein thrombosis), keep MPNs in mind.
- JAK2 isn’t only PV—ET can be JAK2+ too.
- If the vignette emphasizes isolated thrombocytosis, think ET, but always ask: “Could this be reactive?”
Rapid recall (what you should be able to say in 10 seconds)
ET = MPN (JAK2/CALR/MPL) → megakaryocyte proliferation → very high platelets → thrombosis + mucocutaneous bleeding (acquired vWF). Treat with aspirin ± hydroxyurea based on risk.
Frequently Asked Questions
Why can essential thrombocythemia cause both clotting and bleeding?
Essential thrombocythemia can cause both thrombosis and bleeding because the platelet count is very high, but the platelets do not produce a purely pro-clotting state. Increased platelet number and activation promote thrombosis, while extremely high platelet counts can remove high-molecular-weight von Willebrand factor multimers, decreasing platelet adhesion and causing mucocutaneous bleeding such as epistaxis, gum bleeding, and easy bruising.
How do you tell essential thrombocythemia from reactive thrombocytosis?
Essential thrombocythemia is suggested by clonal myeloproliferative features rather than a secondary trigger. It is associated with sustained thrombocytosis, megakaryocytic proliferation in the bone marrow, and driver mutations such as JAK2, CALR, or MPL. Reactive thrombocytosis is secondary to causes like infection, inflammation, iron deficiency, malignancy, or postsplenectomy, and usually has fewer thrombotic and bleeding complications.
What bone marrow and smear findings point to essential thrombocythemia?
The classic findings are marked thrombocytosis on peripheral smear, sometimes with large or giant platelets, plus megakaryocytic proliferation in the bone marrow. The marrow typically shows increased megakaryocytes that are large, mature, and hyperlobulated, often described as having staghorn nuclei. This pattern helps distinguish essential thrombocythemia from other myeloproliferative neoplasms where a different cell line predominates.
What is the usual treatment for essential thrombocythemia on exams?
Treatment is usually low-dose aspirin for microvascular symptoms and thrombosis prevention when appropriate, with hydroxyurea used for cytoreduction in higher-risk patients. Management depends on thrombosis risk and symptoms. If a patient has bleeding with extreme thrombocytosis, the key issue is acquired von Willebrand dysfunction, so platelet reduction may be needed rather than simply adding more antiplatelet therapy.
What clinical clues should make you think of essential thrombocythemia on a vignette?
Think of essential thrombocythemia when a vignette shows isolated thrombocytosis with thrombotic events, mucocutaneous bleeding, or microvascular symptoms. High-yield clues include platelet counts often above 450,000/µL, sometimes above 1,000,000/µL, headache, dizziness, visual changes, erythromelalgia, and unusual thromboses such as Budd–Chiari. Splenomegaly can occur, and JAK2, CALR, or MPL mutations support the diagnosis.